BSX - Boston Scientific Corporation
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 51.07 |
| Open | 51.13 |
| Bid | 51.30 x 1200 |
| Ask | 52.75 x 1200 |
| Day's Range | 50.91 - 51.54 |
| 52 Week Range | 34.98 - 54.17 |
| Volume | |
| Avg. Volume | 9,403,941 |
| Market Cap | 73.725B |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | 86.92 |
| EPS (TTM) | 0.59 |
| Earnings Date | Jul 25, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.40 |
Fair Value
Related Research
ZacksCatalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Insider Monkey15 Healthcare Stocks Billionaires Are Loading Up On
In this article, we discuss 15 best healthcare stocks billionaires are loading up on. You can skip our detailed discussion on the healthcare sector and its performance, and go directly to read 5 Healthcare Stocks Billionaires Are Loading Up On. The healthcare sector in the US is a multifaceted industry that plays a crucial role […]
- Zacks
Inari Medical (NARI) Launches New Catheters to Address VTE
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.
Zacks3 Reasons to Retain Intuitive Surgical (ISRG) Stock for Now
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
ZacksMasimo's (MASI) New FDA Approval to Boost Patient Monitoring
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
ZacksHealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
- Zacks
Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.
ACCESSWIREMeeting the Staff Shortage Crisis With Digital Solutions
Right now, the global healthcare industry faces a worldwide staffing shortage that is roundly expected to worsen.
ZacksHere's Why You Should Retain AMN Healthcare (AMN) Stock for Now
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Simply Wall St.Boston Scientific (NYSE:BSX) shareholders have earned a 8.6% CAGR over the last five years
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
- Zacks
Here's Why You Should Retain PacBio (PACB) Stock for Now
PacBio's (PACB) product development activities raise optimism about the stock.
ZacksVeeva Systems (VEEV) Beats on Q1 Earnings, Ups FY24 Outlook
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performances by both segments.
ZacksHere's Why You Should Retain DaVita (DVA) Stock for Now
Investors remain optimistic about DaVita (DVA) due to the strength of its DaVita Kidney Care.
- Simply Wall St.
Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...
- Zacks
Veeva Systems (VEEV) Extends Tie-Up With Lotus Clinical
Veeva Systems (VEEV) expands its partnership with Lotus Clinical to accelerate clinical trials.
- Zacks
Boston Scientific (BSX) Rises 26.4%: Will the Rally Continue?
Boston Scientific (BSX) gains from strong improvement in organic sales, indicating a solid rebound in the legacy business.
ZacksIs Augmedix (AUGX) Outperforming Other Medical Stocks This Year?
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
PR NewswireBoston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock
Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will automatically convert into shares of the company's common stock on June 1, 2023. As previously disclosed, holders of record at the close of business on May 15, 2023 will separately receive a final quarterly cash dividend of $1.375 per share of preferred stock, payable on June 1, 2023. Following the conversion of the preferred stock, there will be no o
- Zacks
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
ACCESSWIRESix Boston Scientific Benefits That Support Employee Mental Health
NORTHAMPTON, MA / ACCESSWIRE / May 30, 2023 / Boston Scientific One in five American adults has a diagnosable mental health condition. Yet all too often, our friends, co-workers, neighbors and family members suffer emotionally and either don't recognize ...
- Simply Wall St.
Can Boston Scientific Corporation (NYSE:BSX) Performance Keep Up Given Its Mixed Bag Of Fundamentals?
Boston Scientific's (NYSE:BSX) stock is up by 9.1% over the past three months. However, the company's financials look a...
ZacksWhy Is Boston Scientific (BSX) Down 0.9% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative
Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.
ZacksMedtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.
BenzingaRegulatory Hurdles Force Boston Scientific to Opt for Minority Stake in M.I. Tech
Boston Scientific Corporation (NYSE: BSX) is terminating its $230 million plan to buy a majority stake in M.I. Tech, a publicly traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures. The MedTech giant announced acquiring the Korean company in June last year at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. Also Read: Boston Scientific Clocks Strong Q1 Earnings As Elective Surgeries Recover, Boosts FY23 Outlook. “
